Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation

Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation

Bibliographic Details
Main Authors:	R. Gingell, P. Das, Y.P. Teoh
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Atherosclerosis Plus
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667089523000330

Similar Items

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
by: Borislav Borissov, et al.
Published: (2017-01-01)

PCSK9 Targeting in the Management of Hypercholesterolaemia
by: Constantine E. Kosmas, et al.
Published: (2023-10-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023-01-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
by: Assunta Di Costanzo, et al.
Published: (2023-07-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
by: Preiss, D, et al.
Published: (2016)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
by: Albosta MS, et al.
Published: (2023-07-01)

Hypercholesterolaemia treatment in a patient with family hypercholesterolaemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors
by: P. Luque Linero, et al.
Published: (2022-04-01)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
by: Hye Duck Choi, et al.
Published: (2023-01-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
by: Michael Kühl, et al.
Published: (2019-01-01)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
by: Neil, A, et al.
Published: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
by: Neil, H, et al.
Published: (2004)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
by: Neil, H, et al.
Published: (2003)

Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
by: Federica Fogacci, et al.
Published: (2023-12-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
by: Elisa Waldmann, et al.
Published: (2022-01-01)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
by: Elisa Waldmann, et al.
Published: (2022-01-01)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
by: Massimiliano Allevi, et al.
Published: (2023-06-01)

The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia
by: D. Thayabaran, et al.
Published: (2022-10-01)

CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
by: M. Doortje Reijman, et al.
Published: (2024-03-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
by: Samantha K. Sarkar, et al.
Published: (2022-09-01)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
by: Futema, M, et al.
Published: (2014)

Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome
by: Henry, R, et al.
Published: (2014)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
by: Ranheim Trine, et al.
Published: (2007-03-01)

Inclisiran - hope in the fight against dyslipidemia
by: Paulina Krawiec, et al.
Published: (2023-05-01)

Inclisiran: A knight in shining armor?
by: Michael Kelly, et al.
Published: (2022-04-01)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
by: Elena Izkhakov, et al.
Published: (2021-06-01)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
by: Yuansheng Wan, et al.
Published: (2023-12-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
by: Camilla Gustafsen, et al.
Published: (2017-09-01)

Familial hypercholesterolaemia.
by: Gill, P, et al.
Published: (2012)

Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.
by: Arambepola, C, et al.
Published: (2007)

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review
by: Jing Pang, et al.
Published: (2023-03-01)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
by: Noor Shafina Mohd Nor, et al.
Published: (2019-04-01)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
by: Alessia Silla, et al.
Published: (2023-02-01)

Lactobacillus acidophilus NCFM, Inulin, and Oat Bran Reduce TC and LDL-C in Adults with Hypercholesterolaemia
by: Farah Izzati Farush Khan, et al.
Published: (2022)